Truvestments Capital’s DiaMedica Therapeutics DMAC Stock Holding History
Bought
Maintained
Sold
Other funds holding DMAC
Truvestments Capital's DMAC Position: Q3 2026 in Review
Truvestments Capital sold out of DiaMedica Therapeutics (DMAC) in Q3 2026, closing a stake of 9,849 shares — an estimated $69.3K sold.
Truvestments Capital first reported a position in DMAC in Q2 2025 and held it in 5 quarters. The position peaked at $78.4K in Q4 2025. 97 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.
- Truvestments Capital reported no remaining DiaMedica Therapeutics position as of Q3 2026 after selling out during the quarter.
- Truvestments Capital sold 9,849 DiaMedica Therapeutics shares in Q3 2026, an estimated $69.3K.
- Truvestments Capital first reported a position in DiaMedica Therapeutics in Q2 2025 and held it in 5 quarters.
- Truvestments Capital's DiaMedica Therapeutics position peaked at $78.4K in Q4 2025.
- 97 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.
Based on Truvestments Capital's 13F filing for Q3 2026, filed 16 Nov 2026.